Particularly, in the field of pancreatic cancer, a multicenter phase II trial (5-FU, cisplatin, and IFN-α in conjunction with radiation therapy) confirmed the efficacy of IFN-based chemoradiation for PDAC [67]. This evidence concerns the gene IFNA1 and pancreatic neoplasm.